MIFEPREX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mifeprex, and when can generic versions of Mifeprex launch?
Mifeprex is a drug marketed by Danco Labs Llc and is included in one NDA.
The generic ingredient in MIFEPREX is mifepristone. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mifepristone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mifeprex
A generic version of MIFEPREX was approved as mifepristone by GENBIOPRO on April 11th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MIFEPREX?
- What are the global sales for MIFEPREX?
- What is Average Wholesale Price for MIFEPREX?
Summary for MIFEPREX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 87 |
Clinical Trials: | 25 |
Patent Applications: | 4,965 |
DailyMed Link: | MIFEPREX at DailyMed |
Recent Clinical Trials for MIFEPREX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
RTI International | Phase 1 |
Rochester General Hospital | Phase 1 |
Nova Southeastern University | Phase 1 |
US Patents and Regulatory Information for MIFEPREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Danco Labs Llc | MIFEPREX | mifepristone | TABLET;ORAL | 020687-001 | Sep 28, 2000 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MIFEPREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Danco Labs Llc | MIFEPREX | mifepristone | TABLET;ORAL | 020687-001 | Sep 28, 2000 | ⤷ Subscribe | ⤷ Subscribe |
Danco Labs Llc | MIFEPREX | mifepristone | TABLET;ORAL | 020687-001 | Sep 28, 2000 | ⤷ Subscribe | ⤷ Subscribe |
Danco Labs Llc | MIFEPREX | mifepristone | TABLET;ORAL | 020687-001 | Sep 28, 2000 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MIFEPREX
See the table below for patents covering MIFEPREX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 1261262 | METHODE D'INDUCTION DU TRAVAIL OU D'INTERRUPTION D'UNE GROSSESSE, AYANT RECOURS A DES PROSTAGLANDINES ET A UN ANTIPROGESTATIF, ET TAMPONS ET PREPARATIONS UTILISES A CETTE FIN (METHOD OF INDUCING LABOUR OR TERMINATING A PREGNANCY USING A PROSTAGLANDIN AND AN ANTIGESTAGEN AND PACKS AND PREPARATIONS SUITABLE THEREFOR) | ⤷ Subscribe |
Canada | 1220780 | PROCEDE DE PREPARATION DE NOUVEAUX 19-NOR STEROIDES SUBSTITUES EN 11.beta. ET EVENTUELLEMENT EN 2 (PROCESS FOR THE PREPARATION OF NEW 19-NOR STEROIDS SUBSTITUDED IN THE POSITION 11B AND EVENTUALLY 2) | ⤷ Subscribe |
South Korea | 870001936 | ⤷ Subscribe | |
Japan | H0234958 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MIFEPREX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0057115 | SPC/GB93/030 | United Kingdom | ⤷ Subscribe | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
MIFEPREX Market Analysis and Financial Projection Experimental
More… ↓